Replies to post #104930 on Biotech Values

[DewDiligence]

NVS’ CEO Jimenez was on CNBC talking about Gilenya approval today. He emphasized the diversification advantage of NVS, especially they are the second-largest generic drug maker in the world.

Sandoz was NVS’ fastest-growing business segment* during 2Q10, and the launch of generic Lovenox assures that this will continue to be true. Here’s the sales breakdown of NVS’ business segments (from the 2Q10 CC on 7/15/10):



*Excluding the small vaccines & diagnostics segment, which had large one-time sales in 2010 from H1N1.